Cargando…

Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa

BACKGROUND: There is emerging evidence that stimulants warrant further investigation as a treatment for bulimia nervosa (BN) including a recent open-label feasibility trial examining the use of lisdexamfetamine dimestylate (LDX) for BN. The current report presents the secondary outcomes and qualitat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dixon, Laura, Bartel, Sara, Brown, Victoria, Ali, Sarrah I., Gamberg, Susan, Murphy, Andrea, Brewer, Katherine L., McElroy, Susan L., Kaplan, Allan, Nunes, Abraham, Keshen, Aaron R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204259/ https://www.ncbi.nlm.nih.gov/pubmed/37218020 http://dx.doi.org/10.1186/s40337-023-00796-x

Ejemplares similares

Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa
por: Dixon, Laura, et al.
Publicado: (2023)

A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
por: Gasior, Maria, et al.
Publicado: (2017)

Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials
por: McElroy, Susan L, et al.
Publicado: (2016)

Relative Bioavailabilities of Lisdexamfetamine Dimesylate and d-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink
por: Ermer, James, et al.
Publicado: (2016)

A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2014)

Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double‐blind, placebo‐controlled trials in adults with binge‐eating disorder
por: McElroy, Susan L., et al.
Publicado: (2017)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020)

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
por: Pennick, Michael
Publicado: (2010)

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
por: Ermer, James C., et al.
Publicado: (2016)

Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
por: Najib, Jadwiga, et al.
Publicado: (2017)

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009)

The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA
por: Ágh, Tamás, et al.
Publicado: (2016)

Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder
por: Griffiths, Kristi R., et al.
Publicado: (2021)

An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults
por: Ermer, James, et al.
Publicado: (2013)

Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study
por: Ermer, James, et al.
Publicado: (2015)

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
por: Richards, Cynthia, et al.
Publicado: (2018)

Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
por: Guerdjikova, Anna I, et al.
Publicado: (2016)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Banaschewski, Tobias, et al.
Publicado: (2018)

Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2018)

Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use
por: Jain, Rakesh, et al.
Publicado: (2013)

Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2019)

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe
por: Siffel, Csaba, et al.
Publicado: (2020)

Having a history of Anorexia Nervosa: Implications for Bulimia Nervosa treatment
por: Dove, Emma, et al.
Publicado: (2015)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
por: Zimovetz, Evelina A., et al.
Publicado: (2017)

Identification, Characterization and Quantification of Process-Related and Degradation Impurities in Lisdexamfetamine Dimesylate: Identifiction of Two New Compounds
por: Gao, Shenghua, et al.
Publicado: (2018)

Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2020)

Influence of Lisdexamfetamine Dimesylate on Early Ejaculation—Results from a Double-Blind Randomized Clinical Trial
por: Haghighi, Mohammad, et al.
Publicado: (2021)

Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe
por: Coghill, David R., et al.
Publicado: (2017)

Coping strategies therapy for bulimia nervosa
por: Tobin, David L.
Publicado: (2000)

Bulimia Nervosa – medical complications
por: Mehler, Philip S, et al.
Publicado: (2015)

Prevention of hypokalaemia in bulimia nervosa
por: Barron, Leanne, et al.
Publicado: (2015)

Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donors*
por: Pennick, Michael
Publicado: (2013)

Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol
por: Griffiths, Kristi R., et al.
Publicado: (2019)

Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
por: Yee, Karen S., et al.
Publicado: (2020)

Traumatic Brain Injury-Related Attention Deficits in Children: A Controlled Treatment Trial with Lisdexamfetamine Dimesylate (Vyvanse)
por: Tramontana, Michael G., et al.
Publicado: (2021)

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2022)

Treatments of medical complications of anorexia nervosa and bulimia nervosa
por: Mehler, Philip S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ko572m4ose7pgm3saulj0opqbi